Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | PRKG1 | Q13976 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139833 | 1.00 | TACR1 (0.39) | TACR1TAAR1ATMHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL4132585 | 0.99 | TACR1 (0.38) | TACR1TAAR1ATMHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL4132586 | 0.99 | TACR1 (0.38) | TACR1TAAR1ATMHTR2CHTR2B | |
| SCHEMBL4132923 | 0.96 | TACR1 (0.41) | TACR1TAAR1ATMHTR2CHTR2B | |
| SCHEMBL4132921 | 0.96 | TACR1 (0.41) | TACR1TAAR1ATMHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL4132232 | 0.95 | TACR1 (0.40) | TACR1TAAR1ATMHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL4132231 | 0.95 | TACR1 (0.40) | TACR1TAAR1ATMHTR2CHTR2B | |
| SCHEMBL5197246 | 0.92 | TACR1 (0.40) | TACR1TAAR1RENPRKG1 | |
| SCHEMBL4133373 | 0.92 | TACR1 (0.40) | TACR1TAAR1RENPRKG1 | |
| SCHEMBL4133370 | 0.92 | TACR1 (0.40) | TACR1TAAR1RENPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612061-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-11-03 | — | — | US | claimed |
| US-20090076030-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | claimed |
| EP-1710240-B1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | SERVIER LAB (FR) | 2007-12-05 | — | — | EP | claimed |
| US-20060229318-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | US | claimed |
| EP-1710240-A1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | Les Laboratoires Servier (FR) | 2006-10-11 | — | — | EP | claimed |
| US-7612061-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090076030-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-20090075982-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-7465733-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-12-16 | — | — | US | disclosed |
| EP-1710240-B1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | SERVIER LAB (FR) | 2007-12-05 | — | — | EP | disclosed |
| US-20060229318-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | US | disclosed |
| WO-2006106241-A1 | PIPERAZINE DERIVATIVES AND USE THEREOF AS SEROTONIN REUPTAKE INHIBITORS OR AS NEUROKININ ANTAGONISTS | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | WO | disclosed |
| EP-1710240-A1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | Les Laboratoires Servier (FR) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075982-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | TACR1 45/4885TAAR1 77/4885ATM 3151/4885 |
| US-20090076030-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | TACR1 45/4885TAAR1 77/4885ATM 3151/4885 |
| US-20060229318-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | TACR1 45/4885TAAR1 77/4885ATM 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.